Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target

被引：74

作者：

Chong, CR

Qian, DZ

Pan, F

Wei, YF

Pili, R

Sullivan, DJ

Liu, JO ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA

[2] Johns Hopkins Univ, Sch Med, Med Scientist Training Program, Baltimore, MD 21205 USA

[3] Johns Hopkins Univ, Sch Med, Johns Hopkins Clin Compound Screening Initiat, Baltimore, MD 21205 USA

[4] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA

[5] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA

[6] Johns Hopkins Univ, Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Malaria Res Inst,Bloomberg Sch Publ Hlth, Baltimore, MD USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2006年 / 49卷 / 09期

关键词：

D O I：

10.1021/jm051225t

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

To rapidly discover clinically useful angiogenesis inhibitors, we created and screened a library of existing drugs for inhibition of endothelial cell proliferation. Mycophenolic acid (MPA), an immunosuppressive drug, was found to potently inhibit endothelial cell proliferation in Vitro and block tumor-induced angiogenesis in vivo. Using RNA interference, we found that knockdown of one of the two known isoforms of inosine monophosphate dehydrogenase (IMPDH-1) is sufficient to cause endothelial cell cycle arrest.

引用

页码：2677 / 2680

页数：4

共 30 条

[1] Neurologists strike gold in drug screen effort [J].